Natera, Inc. (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 6,000 Shares

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 6,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $143.29, for a total value of $859,740.00. Following the completion of the sale, the insider now owns 143,768 shares in the company, valued at $20,600,516.72. This represents a 4.01 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, January 29th, Solomon Moshkevich sold 5,201 shares of Natera stock. The stock was sold at an average price of $165.87, for a total value of $862,689.87.
• On Wednesday, January 22nd, Solomon Moshkevich sold 24,861 shares of Natera stock. The stock was sold at an average price of $164.97, for a total value of $4,101,319.17.
• On Monday, December 9th, Solomon Moshkevich sold 4,858 shares of Natera stock. The stock was sold at an average price of $166.59, for a total value of $809,294.22.

Natera Trading Down 0.6 %

NASDAQ NTRA opened at $140.66 on Friday. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera, Inc. has a twelve month low of $83.13 and a twelve month high of $183.00. The company has a market cap of $19.02 billion, a price-to-earnings ratio of -79.92 and a beta of 1.80. The business’s fifty day moving average is $166.01 and its 200 day moving average is $147.58.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.01. The business had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. As a group, sell-side analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD raised its position in shares of Natera by 134.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company’s stock worth $1,067,327,000 after acquiring an additional 3,871,862 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Natera by 43.7% in the 4th quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company’s stock worth $1,060,836,000 after acquiring an additional 2,036,396 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Natera by 205.4% in the 3rd quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock worth $355,493,000 after acquiring an additional 1,883,481 shares in the last quarter. Norges Bank bought a new position in shares of Natera in the 4th quarter worth about $224,040,000. Finally, Raymond James Financial Inc. bought a new position in shares of Natera in the 4th quarter worth about $146,419,000. 99.90% of the stock is owned by institutional investors.

Analysts Set New Price Targets

NTRA has been the topic of a number of recent research reports. Canaccord Genuity Group reiterated a “buy” rating and set a $180.00 target price on shares of Natera in a research note on Wednesday, February 26th. Sanford C. Bernstein increased their price target on Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, January 10th. Barclays began coverage on Natera in a research report on Thursday, January 23rd. They set an “overweight” rating and a $200.00 price target on the stock. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a research report on Monday, March 3rd. Finally, TD Cowen increased their price target on Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $173.56.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.